SGLT2 inhibitors are known to reduce diabetic nephropathy risk in patients with type 2 diabetes, but can they also protect against diabetic retinopathy?
In adults with cirrhosis and type 2 diabetes, glucagon-like peptide-1 receptor agonist therapy significantly lowered the risk for death and other adverse outcomes, a study found.
Taiwan: Findings from a recent study published in Diabetes Care showed that patients with type 2 diabetes and discharged with acute liver injury are at significantly more risk of mortality and severe.